ABBV Stock Analysis — AbbVie
Sector: Healthcare
AI Verdict
AbbVie trades at a big discount to the sector on next year's earnings because the market is betting on a massive profit snapback, but if its pipeline stumbles, the stock could quickly look expensive again.
Competitive Moat
AbbVie owns the Humira franchise and a robust immunology pipeline, creating a patent and regulatory moat that slows biosimilar competition. Its scale in immunology and specialty pharma allows it to reinvest in R&D and defend market share.
Summary
A huge drop in forward P/E to 16.8x signals the market expects a dramatic earnings rebound after a tough year.
Where It Stands
AbbVie delivered a 21.27% 1-year return, trades at 16.8x next year's earnings (below the 22x healthcare median), and its RSI of 41.8 suggests shares are cooling but not yet oversold.
Key Metrics
- RSI: 41.8 — Neutral
- Trailing P/E: 70.3x
- Forward P/E: 16.8x
- PEG Ratio: 0.22
- Earnings Growth: +3.2%
- Revenue Growth: +0.1%
- Market Cap: $439.4B
- Dividend Yield: 0.03%
- 1-Year Return: 21.27%
- 52-Week High: $267.47
- 52-Week Low: $190.75
Analyst Consensus
31 Buy · 7 Hold · 0 Sell (38 analysts) · Target $292.67
Bull Case
With analysts forecasting 319.1% forward EPS growth, the current 16.8x forward P/E is cheap for the explosive rebound expected if pipeline launches offset Humira erosion.
Bear Case
If the 319.1% EPS rebound fails to materialize, a fallback to the trailing P/E of 70.3x would mean investors are left paying a huge premium for little growth.
Catalyst to Watch
Watch for clinical trial readouts and FDA decisions on new immunology drugs — positive data could confirm the earnings recovery implied by the low forward P/E.